The authors explain the factors that can cause a failure in a bubble-point integrity test and what to consider when a product-specific bubble point must be defined.
Brian K. Meyer
Advertisement
Brian K. Meyer is a research fellow at Merck & Co., 770 Sumneytown Pike, West Point, PA 19486, tel. 215.652.3992, fax 215.652.5299.
Articles by Brian K. Meyer
Advertisement
Latest Updated Articles
Establishing Material Compatibility, Process Conditions, and Bubble Points of FiltersPublished: November 1st 2008 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
2
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
3
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
4
AAPS PharmSci 360 2025: Trends in Bioanalysis
5
